Aliceblue ANTInstall and trade smarter everywhere
Complete IPO details, including price band, financials, subscription status, and key insights.
Participate in the Nephrocare Health Services Ltd IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.
Key metrics and details at a glance.
Price Band
₹460
Per ShareLot Size
32 Shares
Minimum Investment
₹14,720
Issue Size
₹871.05 Cr
Face Value
₹2
Per ShareIPO Type
Book Building
Retail Quota
35%
QIB Quota
50%
NII Quota
15%
Important dates for your applying strategy.
Business model, operations, and market positioning.
Promoter Holding (Pre-Issue)
77.29%
Promoter Holding (Post-Issue)
66.72%
Issue Type
Book Building
ISIN
INE428V01029
We offer comprehensive dialysis care through our network of clinics from diagnosis to treatment and wellness programs including haemodialysis, home and mobile dialysis, supported by pharmacy. We are India's largest dialysis service provider in terms of number of patients served, clinics, cities covered, treatments performed, revenue, and EBITDA (excluding other income) in Fiscal 2025. (Source: F&S Report) In Fiscal 2025, we served 29,281 patients and completed 2,885,450 treatments in India which represented approximately 10% of the total dialysis patients in India. We have a global network of 519 clinics and are the most widely distributed dialysis network in India with an extensive pan-India network of clinics across 288 cities, as of September 30, 2025 (Source: F&S Report) and 21 States and four Union Territories. In the six months period ended September 30, 2025 and Fiscal 2025, 2024, and 2023, our revenue from operations was Rs. 4,735.01 million, Rs. 7,558.12 million, Rs. 5,661.55 million and Rs. 4,372.95 million, respectively, highest amongst major organized dialysis service chains in India (Source: F&S Report). Our Profit / (loss) for the period / year was Rs. 142.28 million, Rs. 670.96 million, Rs. 351.33 million and Rs. (117.89) million in the six months period ended September 30, 2025, Fiscals 2025, 2024 and 2023, respectively. Our EBITDA (excluding other income) has consistently increased and was Rs. 1,103.10 million, Rs. 1,666.37 million, Rs. 996.58 million and Rs. 485.95 million in the six months period ended September 30, 2025, Fiscals 2025, 2024 and 2023, respectively.
Revenue, profit after tax and total assets across the last 3 reported financial years.
Amount in ₹ crore
How the company plans to utilize IPO proceeds.
The funds raised through this IPO will be used for:
Initial public offering of 18,943,020 equity shares of face value of Rs.2/- each ("equity shares") of Nephrocare Health Services Limited ("the company" or the "company" or the "issuer") for cash at a price of Rs.460/- per equity share face value of Rs.2/- (including a securities premium of Rs.458/- per equity share) ("offer price") aggregating to Rs.871.05 crores ("offer") comprising a fresh issue of 7,690,162 equity shares of face value of Rs.2/- each aggregating to Rs.353.41 crores ("fresh issue") and an offer for sale of 11,253,102 equity shares of face value of Rs.2/- each ("offered shares") aggregating to Rs.517.64 crores , comprising an offer for sale of 1,521,728 equity shares of face value of Rs.2/- each aggregating to Rs.70.00 crores by Investcorp Private Equity Fund II and 1,604,907 equity shares of face value of Rs.2/- each aggregating to Rs.73.83 crores by Healthcare Parent Limited and 147,765 equity shares of face value of Rs.2/- each aggregating to Rs.6.80 crores by Investcorp Growth Opportunity Fund and 2,888,911 equity shares of face value of Rs.2/- each aggregating to Rs.132.89 crores by Edoras Investment Holdings Pte. Ltd. ("promoter selling shareholders") and 121,985 equity shares of face value of Rs.2/- each aggregating to Rs.5.61 crores by Investcorp India Private Equity Opportunity Limited and 3,089,663 equity shares of face value of Rs.2/- each aggregating to Rs.142.12 crores by International Finance Coproration and 1,433,468 equity shares of face value of Rs.2/- each aggregating to Rs.65.94 crores by 360 One Special Opportunities Fund - Series 9 and 444,675 equity shares of face value of Rs.2/- each aggregating to Rs.20.46 crores by 360 One Special Opportunities Fund - Series 10 ("other selling shareholders" and together with the promoter selling shareholders, the "selling shareholders" and such offer for sale by the selling shareholders, the "offer for sale"). The offer constituted 18.88% of the post-offer paid-up equity share capital of the company.
*Subject to approvals and market conditions.
Key competitive advantages and factors to consider before investing.
Live demand across investor categories.
Track real-time subscription levels:
*Real-time data subject to exchange updates
The global revenue from dialysis services was estimated to be around USD 75.20 billion in 2024 and it is estimated to grow at a CAGR of 7.1% during the forecast period (2024 to 2029) to reach around USD 106.2 billion by 2029 driven by factors such as increasing prevalence of CKD, improved diagnosis of ESRD and increasing access to dialysis service. The total number of dialysis patients is expected to increase from 0.28 million in 2024 to 0.52 million by 2029, growing at a CAGR of 12.7%.
Our Company was incorporated as "Nephrocare Health Services Private Limited", a private limited company under the Companies Act, 1956, at Hyderabad with a certificate of incorporation issued by the Assistant Registrar of Companies, Andhra Pradesh ("RoC Andhra Pradesh") on December 18, 2009. Pursuant to resolutions dated April 11, 2025 and June 2, 2025 passed by our Board and Shareholders, respectively, our Company was converted into a public limited company and consequently, the name of our Company was changed to "Nephrocare Health Services Limited" with a fresh certificate of incorporation dated June 18, 2025 issued by the Registrar of Companies, Central Registration Centre.
Wholesaler and Retailer
Amount in ₹ crore
Amount in ₹ crore
Figures in ₹ crore, on a consolidated basis, as reported for FY24 to FY26.